{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T07:28:35Z","timestamp":1776842915589,"version":"3.51.2"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"GILEAD SCIENCES, Spain","award":["6\u00aa Convocatoria de Becas Gilead a proyectos de Microeliminaci\u00f3n en Hepatitis C y Epidemiolog\u00eda en Hepatitis D 2023"],"award-info":[{"award-number":["6\u00aa Convocatoria de Becas Gilead a proyectos de Microeliminaci\u00f3n en Hepatitis C y Epidemiolog\u00eda en Hepatitis D 2023"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The Spanish National Health System, with devolved powers to autonomous communities such as Catalonia, faces significant challenges in controlling viral infections like hepatitis C (HCV) among vulnerable groups, particularly people who inject drugs (PWID), where prisons serve as crucial intervention sites. Catalonia\u2019s health authorities have implemented strategies to combat HCV, including direct-acting antiviral (DAA) treatments and harm reduction programmes within both community and penitentiary settings. However, substantial barriers persist in achieving full treatment uptake and clearance among PWID subpopulations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Main body<\/jats:title>\n            <jats:p>This review aims to discuss the Catalonia\u2019s current HCV programmes and explores intervention proposals needed to achieve WHO elimination targets. Catalonia has implemented a comprehensive HCV plan, particularly targeting PWID, that has proven effective through enhanced screening, universal treatment access, and harm reduction, though structural and social barriers remain due to fragmented health and social systems.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Advancing towards HCV elimination requires strengthened inter-organisational coordination, integrated social and health services, simplified care pathways, enhanced screening, professional training, targeted research, measurable goals, culturally appropriate and participatory prevention strategies, and a comprehensive, people-centred approach. This is particularly important in prisons, where universal screening, adapted caring processes, harm reduction, and opioid substitution treatments (OST) are essential. Considering the social determinants of health perspective, it is essential that policies and programs are structured to reduce structural inequities and vulnerabilities, thereby promoting equity in both access to prevention, care, treatment, and health benefits across all population groups, particularly those most affected.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12954-025-01286-w","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T04:13:50Z","timestamp":1753935230000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["How to eliminate hepatitis C between people who inject drugs in community services and prisons in Catalonia"],"prefix":"10.1186","volume":"22","author":[{"given":"Elena","family":"Yela","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5268-3574","authenticated-orcid":false,"given":"Daniel G.","family":"Abi\u00e9tar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Clua-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"key":"1286_CR1","unstructured":"Ministry of Health, Social Services and Equality (MHSSE). Strategic plan for tackling hepatitis c in the Spanish national health system. Madrid: Ministry of Health, Social Services and Equality. 2015. (Accessed April 26, 2025). Availa ble at: https:\/\/www.sanidad.gob.es\/ciudadanos\/enfLesiones\/enfTransmisibles\/hepatitisC\/PlanEstrategicoHEPATITISC\/docs\/PEAHC_eng.pdf"},{"key":"1286_CR2","unstructured":"Mart\u00ednez Alonso JL, Teira Esmatges N, Lletj\u00f3s-Botey P, Mansilla-Lou R. Pla d\u2019acci\u00f3 enfront de la infecci\u00f3 pel VIH i les altres ITS 2021\u20132030. Barcelona: Generalitat de Catalunya. Departament de Salut, 2022. (Accessed April 26, 2025) Able at: https:\/\/scientiasalut.gencat.cat\/bitstream\/handle\/11351\/9238\/pla_accio_enfront_vih_altres_its_2021_2030_2021.pdf?sequence=1&isAllowed=y"},{"key":"1286_CR3","unstructured":"Ag\u00e8ncia de Salut P\u00fablica de Catalunya. Programa de prevenci\u00f3, control i Atenci\u00f3 al virus d\u2019immunodefici\u00e8ncia humana, les infeccions de transmissi\u00f3 sexual (ITS) i les hepatitis v\u00edriques (HV). Protocol de diagn\u00f2stic i tractament Del virus de l\u2019hepatitis C per persones drogodependents. Ag\u00e8ncia De Salut P\u00fablica De Catalunya. 2021. Available at: https:\/\/salutpublica.gencat.cat\/web\/.content\/minisite\/aspcat\/vigilancia_salut_publica\/vih-sida-its\/04_Hepatitis_viriques\/guies_i_protocols\/Protocol-diagnostic-i-tractament-VHC-persones-drogodependents_Act-2021_okDef.pdf"},{"key":"1286_CR4","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/jvh.13220","volume":"27","author":"M Yanes-Lane","year":"2020","unstructured":"Yanes-Lane M, Dussault C, Linthwaite B, Cox J, Klein M, Sebastiani G, Lebouch\u00e9 B, Kronfli N. Using the barriers and facilitators to linkage to HIV care to inform hepatitis C virus (HCV) linkage to care strategies for people released from prison: findings from a systematic review. J Viral Hepatitis. 2020;27:205\u201320. https:\/\/doi.org\/10.1111\/jvh.13220.","journal-title":"J Viral Hepatitis"},{"key":"1286_CR5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.drugpo.2019.05.014","volume":"72","author":"A Marco","year":"2019","unstructured":"Marco A, Guerrero RA, Vergara M, Gallego C, Sol\u00e9 C, Planella R, Vaz ME, Teixid\u00f3 N, Sastre A, Touz\u00f3n C, da Silva A, Almada G, Ru\u00edz A, Cayl\u00e0 JA, Turu E. Reinfection in a large cohort of prison inmates with sustained virological response after treatment of chronic hepatitis C in Catalonia (Spain), 2002\u20132016. Int J Drug Policy. 2019;72:189\u201394. https:\/\/doi.org\/10.1016\/j.drugpo.2019.05.014.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"1286_CR6","first-page":"27","volume":"45","author":"R Clua Garc\u00eda","year":"2022","unstructured":"Clua Garc\u00eda R, Salcedo D, Garc\u00eda M, Peralta E. Atenci\u00f3n de enfermer\u00eda a usuarios de drogas en prisi\u00f3n. Revista Rol De Enfermer\u00eda. 2022;45(1):27\u201332.","journal-title":"Revista Rol De Enfermer\u00eda"},{"key":"1286_CR7","volume-title":"Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022\u20132030","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022\u20132030. Geneva: World Health Organization; 2022."},{"key":"1286_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jsat.2017.03.003","volume":"77","author":"O Par\u00e9s-Badell","year":"2017","unstructured":"Par\u00e9s-Badell O, Espelt A, Folch C, Maj\u00f3 X, Gonz\u00e1lez V, Casabona J, Brugal MT. Undiagnosed HIV and hepatitis C infection in people who inject drugs: from new evidence to better practice. J Subst Abuse Treat. 2017;77:13\u201320. https:\/\/doi.org\/10.1016\/j.jsat.2017.03.003.","journal-title":"J Subst Abuse Treat"},{"key":"1286_CR9","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.drugpo.2019.10.012","volume":"74","author":"V Saludes","year":"2019","unstructured":"Saludes V, Antuori A, Folch C, Gonz\u00e1lez N, Ib\u00e1\u00f1ez N, Maj\u00f3 X, Colom J, Matas L, Casabona J, Martr\u00f3, E & HepCdetect II Study Group. Utility of a one-step screening and diagnosis strategy for viremic HCV infection among people who inject drugs in Catalonia. Int J Drug Policy. 2019;74:236\u201345. https:\/\/doi.org\/10.1016\/j.drugpo.2019.10.012.","journal-title":"Int J Drug Policy"},{"key":"1286_CR10","unstructured":"Comissi\u00f3 per a l\u2019elaboraci\u00f3 del pla de prevenci\u00f3 i control de l\u2019hepatitis C a Catalunya. 2019. Generalitat de Catalunya. Departament de Salut. (Accessed April 26, 2025) Aviable at: https:\/\/salutpublica.gencat.cat\/web\/.content\/minisite\/aspcat\/vigilancia_salut_publica\/vih-sida-its\/04_Hepatitis_viriques\/Pla-Hepatitis-Definitiu_C_DEF.pdf"},{"issue":"1","key":"1286_CR11","doi-asserted-by":"publisher","first-page":"38","DOI":"10.4321\/s1575-06202019000100006","volume":"21","author":"A Marco","year":"2019","unstructured":"Marco A, Guerrero RA, Turu E, Gallego C, Teixid\u00f3 N, Sastre A, Cayl\u00e0 JA, GRUMIP. Is it possible to eliminate hepatitis C from the prisons of Catalonia, Spain, in 2021? Revista Espa\u00f1ola de Sanidad Penitenciaria. 2019;21(1):38\u201341. https:\/\/doi.org\/10.4321\/s1575-06202019000100006","journal-title":"Revista Espa\u00f1ola De Sanidad Penitenciaria"},{"issue":"12","key":"1286_CR12","doi-asserted-by":"publisher","first-page":"100580","DOI":"10.1016\/j.jhepr.2022.100580","volume":"4","author":"S Lens","year":"2022","unstructured":"Lens S, Miralpeix A, G\u00e1lvez M, Martr\u00f3 E, Gonz\u00e1lez N, Rodr\u00edguez-Tajes S, Mari\u00f1o Z, Saludes V, Reyes-Urue\u00f1a J, Maj\u00f3 X, Colom J, Forns X. HCV microelimination in harm reduction centres has benefits beyond HCV cure but is hampered by high reinfection rates. JHEP Reports: Innov Hepatol. 2022;4(12):100580. https:\/\/doi.org\/10.1016\/j.jhepr.2022.100580.","journal-title":"JHEP Reports: Innov Hepatol"},{"key":"1286_CR13","doi-asserted-by":"publisher","first-page":"502288","DOI":"10.1016\/j.gastrohep.2024.502288","volume":"502288","author":"A Miralpeix","year":"2024","unstructured":"Miralpeix A, Ib\u00e1\u00f1ez P, Navarro V, Colomera P, G\u00e1lvez M, Mari\u00f1o Z, Major X, Colom J, Forns X, Lens S. Externalised nurse-led model for hepatitis C virus microelimination and impact of drug use profile. Gastroenterol Hepatol. 2024;502288:502288. https:\/\/doi.org\/10.1016\/j.gastrohep.2024.502288.","journal-title":"Gastroenterol Hepatol"},{"issue":"1","key":"1286_CR14","doi-asserted-by":"publisher","first-page":"16012","DOI":"10.1038\/s41598-023-42701-1","volume":"13","author":"V Saludes","year":"2023","unstructured":"Saludes V, Bordoy AE, Yela E, Tur\u00fa E, Not A, L\u00f3pez-Corbeto E, Egea-Cort\u00e9s L, Gonz\u00e1lez-Candelas F, Casabona J. Group for the study and control of infectious diseases in prison (GRUMIP), Marco A & Martr\u00f3 E. Incidence and molecular epidemiology of hepatitis C virus reinfection in prisons in Catalonia, Spain (Re-HCV study). Sci Rep. 2023;13(1):16012. https:\/\/doi.org\/10.1038\/s41598-023-42701-1","journal-title":"Sci Rep"},{"issue":"9","key":"1286_CR15","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1111\/jgh.14984","volume":"35","author":"S Rodr\u00edguez-Tajes","year":"2020","unstructured":"Rodr\u00edguez-Tajes S, Dom\u00ednguez \u00c1, Carri\u00f3n JA, Buti M, Quer JC, Morillas RM, L\u00f3pez C, Torras X, Baliellas C, Vergara M, Forner M, Zaragoza N, Sal\u00f2 J, Rigau J, Caballeria L, Mari\u00f1o Z, Jan\u00e8 M, Colom J, Forns X, Lens S. Significant decrease in the prevalence of hepatitis C infection after the introduction of direct acting antivirals. J Gastroenterol Hepatol. 2020;35(9):1570\u20138. https:\/\/doi.org\/10.1111\/jgh.14984.","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"1286_CR16","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/jvh.13427","volume":"28","author":"J Reyes-Urue\u00f1a","year":"2021","unstructured":"Reyes-Urue\u00f1a J, Celly A, Moreno S, Maj\u00f3 X, Colom J, Casabona J. Hepatitis C virus: testing rate and attrition at linkage to specialized care, Catalonia, Spain 2011\u20132016. J Viral Hepatitis. 2021;28(2):288\u201399. https:\/\/doi.org\/10.1111\/jvh.13427","journal-title":"J Viral Hepatitis"},{"key":"1286_CR17","doi-asserted-by":"publisher","unstructured":"S\u00f6nmez I, Espelt A, Maj\u00f3 X, Bartroli M, Mero\u00f1o MC, Gonz\u00e1lez V, Gotsens M, Garrido A, Colom J, Casabona J, Folch C. Trends in the prevalence of HIV, HCV, and co-infection and associated factors among young people who inject drugs (PWID) in Catalonia (2008\u20132019). Vulnerable Child Youth Stud. 2024;1\u201315. https:\/\/doi.org\/10.1080\/17450128.2024.2390593.","DOI":"10.1080\/17450128.2024.2390593"},{"issue":"2","key":"1286_CR18","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3109\/10826084.2015.1092991","volume":"51","author":"C Folch","year":"2016","unstructured":"Folch C, Casabona J, Espelt A, Maj\u00f3 X, Mero\u00f1o M, Gonzalez V, Wiessing L, Colom J, Brugal MT, REDAN Study Group. High prevalence and incidence of HIV and HCV among new injecting drug users with a large proportion of migrants, is prevention failing? Subst Use Misuse. 2016;51(2):250\u201360. https:\/\/doi.org\/10.3109\/10826084.2015.1092991.","journal-title":"Subst Use Misuse"},{"key":"1286_CR19","doi-asserted-by":"publisher","first-page":"103057","DOI":"10.1016\/j.drugpo.2020.103057","volume":"90","author":"C Folch","year":"2021","unstructured":"Folch C, Saludes V, Reyes-Ure\u00f1a J, Antuori A, Ib\u00e1\u00f1ez N, Maj\u00f3 X, Colom J, Matas L, Casabona J, Martr\u00f3 E, HepCdetect II Study Group. The hepatitis C care cascade among people who inject drugs accessing harm reduction services in Catalonia: major gaps for migrants. Int J Drug Policy. 2021;90:103057. https:\/\/doi.org\/10.1016\/j.drugpo.2020.103057","journal-title":"Int J Drug Policy"},{"issue":"3","key":"1286_CR20","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/jvh.12809","volume":"25","author":"V Saludes","year":"2018","unstructured":"Saludes V, Folch C, Morales-Carmona A, Ferrer L, Fern\u00e1ndez-L\u00f3pez L, Mu\u00f1oz R, Jim\u00e9nez M, Loureiro E, Fern\u00e1ndez-D\u00e1vila P, Bascu\u00f1ana E, Casabona J, Martr\u00f3 E. Community-based screening of hepatitis C with a one-step RNA detection algorithm from dried-blood spots: analysis of key populations in barcelona, Spain. J Viral Hepatitis. 2018;25(3):236\u201344. https:\/\/doi.org\/10.1111\/jvh.12809.","journal-title":"J Viral Hepatitis"},{"key":"1286_CR21","unstructured":"Fern\u00e1ndez-L\u00f3pez L, Reyes-Ure\u00f1a J, Folch-Toda C, Ib\u00e1\u00f1ez-Mart\u00ednez N, Maj\u00f3-Roca X, Buira E. Protocol de la prova de detecci\u00f3 r\u00e0pida del VHC per a HSH i persones trans. Barcelona: Sub-direcci\u00f3 General de Drogodepend\u00e8ncies, 2018. (Accessed April 26, 2025) Available at: https:\/\/salutpublica.gencat.cat\/web\/.content\/minisite\/aspcat\/vigilancia_salut_publica\/vih-sida-its\/04_Hepatitis_viriques\/guies_i_protocols\/Protocol-HSH-i-persones-Trans.pdf"},{"key":"1286_CR22","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.3390\/ijerph18041762","volume":"18","author":"F Calvo","year":"2021","unstructured":"Calvo F, Turr\u00f3-Garriga O, F\u00e0bregas C, Alfranca R, Calvet A, Salvans M, Giralt C, Castillejos S, Rived-Oca\u00f1a M, Calvo P, et al. Mortality risk factors for individuals experiencing homelessness in Catalonia (Spain): A 10-Year retrospective cohort study. Int J Environ Res Public Health. 2021;18:1762. https:\/\/doi.org\/10.3390\/ijerph18041762.","journal-title":"Int J Environ Res Public Health"},{"key":"1286_CR23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.drugpo.2018.09.008","volume":"62","author":"C Folch","year":"2018","unstructured":"Folch C, Lorente N, Maj\u00f3 X, Par\u00e9s-Badell O, Roca X, Brugal T, Roux P, Carrieri P, Colom J, Casabona J, REDAN study group. Drug consumption rooms in Catalonia: A comprehensive evaluation of social, health and harm reduction benefits. Int J Drug Policy. 2018;62:24\u20139. https:\/\/doi.org\/10.1016\/j.drugpo.2018.09.008","journal-title":"Int J Drug Policy"},{"key":"1286_CR24","unstructured":"Marco A, Yela E, Bullich C, Freixenet X, Guerrero RA, Turu E, GRUMIP. &. Infecci\u00f3n por VHC conocida y oculta en los ingresados en las prisiones de Catalu\u00f1a. Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica, 2019; 37 (especial congreso 2):3. (Accessed April 26, 2025) Available at: https:\/\/static.elsevier.es\/miscelanea\/gehep_completo2019.pdf"},{"issue":"3","key":"1286_CR25","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/jvh.13634","volume":"29","author":"X Forns","year":"2022","unstructured":"Forns X, Colom J, Garc\u00eda-Retortillo M, Quer JC, Lens S, Martr\u00f3 E, Dom\u00ednguez-Hern\u00e1ndez R, Casado M\u00c1. Buti M.Point-of-care hepatitis C testing and treatment strategy for people attending harm reduction and addiction centres for hepatitis C elimination. J Viral Hepatitis. 2022;29(3):227\u201330. https:\/\/doi.org\/10.1111\/jvh.13634.","journal-title":"J Viral Hepatitis"},{"issue":"38","key":"1286_CR26","doi-asserted-by":"publisher","first-page":"5874","DOI":"10.3748\/wjg.v26.i38.5874","volume":"26","author":"A Sanvisens","year":"2020","unstructured":"Sanvisens A, Rivas I, Faure E, Espinach N, Hernandez-Rubio A, Maj\u00f3 X, Colom J, Muga R. Monitoring hepatitis C virus treatment rates in an opioid treatment program: A longitudinal study. World J Gastroenterol. 2020;26(38):5874\u201383. https:\/\/doi.org\/10.3748\/wjg.v26.i38.5874.","journal-title":"World J Gastroenterol"},{"issue":"Suppl 1","key":"1286_CR27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.gaceta.2016.04.020","volume":"30","author":"M Bosque-Prous","year":"2016","unstructured":"Bosque-Prous M, Brugal MT. Intervenciones de reducci\u00f3n de da\u00f1os en usuarios de drogas: situaci\u00f3n actual y recomendaciones. Gac Sanit. 2016;30(Suppl 1):99\u2013105. https:\/\/doi.org\/10.1016\/j.gaceta.2016.04.020","journal-title":"Gac Sanit"},{"key":"1286_CR28","unstructured":"Generalitat de Catalunya D, de Salut. Observatori sobre drogues i addiccions comportamentals. Informe Sistema d\u2019Informaci\u00f3 sobre Addiccions de Catalunya: Informe anual 2023. Barcelona: Generalitat de Catalunya; 2024 Jun [cited 2025 Jul 5]. Available at: https:\/\/drogues.gencat.cat\/web\/.content\/minisite\/drogues\/professionals\/observatori\/2024\/Informe-OCDA-2023.pdf"},{"key":"1286_CR29","unstructured":"Harm Reduction International. Global State of Harm Reduction 2022. London: Harm Reduction International. 2022. (Accessed April 26, 2025) Available at: https:\/\/hri.global\/wp-content\/uploads\/2022\/11\/HRI_GSHR-2022_Full-Report_Final.pdf"},{"issue":"1","key":"1286_CR30","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12954-024-01009-7","volume":"21","author":"E Yela","year":"2024","unstructured":"Yela E, Sol\u00e9 N, Puig L, L\u00f3pez Gallegos D, Clua-Garc\u00eda R. Barriers to access to hepatitis C treatment with direct-acting antivirals in people who inject drugs in the community setting. Harm Reduct J. 2024;21(1):88. https:\/\/doi.org\/10.1186\/s12954-024-01009-7.","journal-title":"Harm Reduct J"},{"issue":"1","key":"1286_CR31","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12954-020-00429-5","volume":"17","author":"S Shirley-Beavan","year":"2020","unstructured":"Shirley-Beavan S, Roig A, Burke-Shyne N, Daniels C, Csak R. Women and barriers to harm reduction services: a literature review and initial findings from a qualitative study in Barcelona, Spain. Harm Reduct J. 2020;17(1):78. https:\/\/doi.org\/10.1186\/s12954-020-00429-5","journal-title":"Harm Reduct J"},{"key":"1286_CR32","unstructured":"Sheehan Y, Garg A, Sheehan J, Maduka N, Altice FL, Alves da Costa F et al.. Global Guidelines for Viral Hepatitis Service Delivery in Prisons. International Network on Health and Hepatitis in Substance Users\u2013 Prisons (INHSU Prisons), August 2024. Accessed April 26(2025). Available at: https:\/\/inhsu.org\/wp-content\/uploads\/2024\/09\/Global-Guidelines_FINAL.pdf"},{"issue":"1","key":"1286_CR33","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12954-016-0118-x","volume":"13","author":"G Sander","year":"2016","unstructured":"Sander G, Scandurra A, Kamenska A, MacNamara C, Kalpaki C, Bessa CF, Laso GN, Parisi G, Varley L, Wolny M, Moudatsou M, Pontes NH, Mannix-McNamara P, Libianchi S, Antypas T. Overview of harm reduction in prisons in seven European countries. Harm Reduct J. 2016;13(1):28. https:\/\/doi.org\/10.1186\/s12954-016-0118-x.","journal-title":"Harm Reduct J"},{"issue":"2","key":"1286_CR34","doi-asserted-by":"publisher","first-page":"66","DOI":"10.18176\/resp.00012","volume":"22","author":"A Marco","year":"2020","unstructured":"Marco A, Dom\u00ednguez-Hern\u00e1ndez R, Casado MA. Cost-effectiveness analysis of chronic hepatitis C treatment in the prison population in Spain. Revista Espa\u00f1ola De Sanidad Penitenciaria. 2020;22(2):66\u201374. https:\/\/doi.org\/10.18176\/resp.00012.","journal-title":"Revista Espa\u00f1ola De Sanidad Penitenciaria"},{"issue":"2","key":"1286_CR35","doi-asserted-by":"publisher","first-page":"e90560","DOI":"10.1371\/journal.pone.0090560","volume":"9","author":"A Marco","year":"2014","unstructured":"Marco A, Gallego C, Cayl\u00e0 JA. Incidence of hepatitis C infection among prisoners by routine laboratory values during a 20-year period. PLoS ONE. 2014;9(2):e90560. https:\/\/doi.org\/10.1371\/journal.pone.0090560.","journal-title":"PLoS ONE"},{"issue":"3","key":"1286_CR36","doi-asserted-by":"publisher","first-page":"153","DOI":"10.4321\/s1575-06202019000300006","volume":"21","author":"E Turu","year":"2019","unstructured":"Turu E, Barn\u00e9s I, Marco A. Asistencial and therapeutic continuity after release from prison: an urgent problem that requires solutions. The model applied in Catalonian prisons. Revista Espa\u00f1ola De Sanidad Penitenciaria. 2019;21(3):153\u201360. https:\/\/doi.org\/10.4321\/s1575-06202019000300006.","journal-title":"Revista Espa\u00f1ola De Sanidad Penitenciaria"},{"key":"1286_CR37","doi-asserted-by":"publisher","first-page":"16849","DOI":"10.1038\/s41598-019-52564-0","volume":"9","author":"OO Dalgic","year":"2019","unstructured":"Dalgic OO, Samur S, Spaulding AC, Llerena S, Cobo C, Ayer T, Roberts MS, Crespo J, Chhatwal J. Improved health outcomes from hepatitis C treatment Scale-Up in Spain\u2019s prisons: A Cost-Effectiveness study. Sci Rep. 2019;9:16849. https:\/\/doi.org\/10.1038\/s41598-019-52564-0","journal-title":"Sci Rep"},{"issue":"5","key":"1286_CR38","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3390\/diagnostics11050877","volume":"11","author":"J Cabezas","year":"2021","unstructured":"Cabezas J, Llerena S, Mateo M, \u00c1lvarez R, Cobo C, Gonz\u00e1lez V, Martr\u00f3 E, Cuadrado A, Crespo J. Hepatitis C micro-elimination beyond prison walls: navigator- assisted test-and-treat strategy for subjects serving non- custodial sentences. Diagnostics (Basel). 2021;11(5):877. https:\/\/doi.org\/10.3390\/diagnostics11050877","journal-title":"Diagnostics (Basel)"},{"issue":"7","key":"1286_CR39","doi-asserted-by":"publisher","first-page":"565","DOI":"10.17235\/reed.2020.7108\/2020","volume":"112","author":"J Crespo","year":"2020","unstructured":"Crespo J, Tejerina Puente A, Cuadrado A, Llerena S, Cabezas J. Grupo de trabajo para la eliminaci\u00f3n de la hepatitis C enCantabria. Strategy for the elimination of hepatitis C in Cantabria. Rev Esp Enferm Dig. 2020;112(7):565\u201370. https:\/\/doi.org\/10.17235\/reed.2020.7108\/2020","journal-title":"Rev Esp Enferm Dig"},{"key":"1286_CR40","doi-asserted-by":"publisher","first-page":"175628482110165","DOI":"10.1177\/17562848211016563","volume":"14","author":"L Grau-L\u00f3pez","year":"2021","unstructured":"Grau-L\u00f3pez L, Marcos-Fosch C, Daigre C, Palma-Alvarez RF, Rando-Segura A, Llaneras J, Perea-Ortueta M, Rodriguez-Frias F, Mart\u00ednez-Luna N, Riveiro-Barciela M, Ramos-Quiroga JA, Colom J, Esteban R, Buti M. Barriers to linkage to care in hepatitis C patients with substance use disorders and dual diagnoses, despite centralized management. Therapeutic Adv Gastroenterol. 2021;14:17562848211016563. https:\/\/doi.org\/10.1177\/17562848211016563.","journal-title":"Therapeutic Adv Gastroenterol"},{"key":"1286_CR41","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1007\/s13178-022-00702-1","volume":"20","author":"L De La Mora","year":"2023","unstructured":"De La Mora L, Laguno M, De Lazzari E, Ugarte A, Leal L, Torres B, et al. Vulnerability conditions in a cohort of men who have sex with men who engage in chemsex in Barcelona city: a cross-sectional study. Sexuality Res Social Policy. 2023;20:614\u201325. https:\/\/doi.org\/10.1007\/s13178-022-00702-1.","journal-title":"Sexuality Res Social Policy"},{"issue":"9","key":"1286_CR42","doi-asserted-by":"publisher","first-page":"e0238963","DOI":"10.1371\/journal.pone.0238963","volume":"15","author":"JE Ospina","year":"2020","unstructured":"Ospina JE, Orcau \u00c0, Millet JP, Ros M, Gil S, Cayl\u00e0 JA, Barcelona Tuberculosis Immigration Working Group. Correction: Epidemiology of tuberculosis in immigrants in a large city with large- scale immigration (1991\u20132013). PLoS ONE. 2020;15(9):e0238963. https:\/\/doi.org\/10.1371\/journal.pone.0238963","journal-title":"PLoS ONE"},{"key":"1286_CR43","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/1471-2458-12-158","volume":"12","author":"JE Ospina","year":"2012","unstructured":"Ospina JE, Orcau A, Millet JP, S\u00e1nchez F, Casals M, Cayl\u00e0 JA. Community health workers improve contact tracing among immigrants with tuberculosis in Barcelona. BMC Public Health. 2012;12:158. https:\/\/doi.org\/10.1186\/1471-2458-12-158.","journal-title":"BMC Public Health"},{"issue":"1","key":"1286_CR44","first-page":"75","volume":"46","author":"R Clua Garc\u00eda","year":"2021","unstructured":"Clua Garc\u00eda R. Razones de las pr\u00e1cticas de riesgo en usuarios de drogas por v\u00eda parenteral de programas de reducci\u00f3n de da\u00f1os en Barcelona. Revista Espa\u00f1ola De Drogodependencias. 2021;46(1):75\u201389.","journal-title":"Revista Espa\u00f1ola De Drogodependencias"},{"key":"1286_CR45","doi-asserted-by":"publisher","first-page":"102772","DOI":"10.1016\/j.drugpo.2020.102772","volume":"81","author":"JM Montero-Moraga","year":"2020","unstructured":"Montero-Moraga JM, Garrido-Albaina A, Barbaglia MG, Gotsens M, Aranega D, Espelt A, Par\u00e9s-Badell O. Impact of 24-hour schedule of a drug consumption room on service use and number of non-fatal overdoses. A quasiexperimental study in Barcelona. Int J Drug Policy. 2020;81:102772. https:\/\/doi.org\/10.1016\/j.drugpo.2020.102772.","journal-title":"Int J Drug Policy"},{"key":"1286_CR46","doi-asserted-by":"publisher","DOI":"10.1177\/14661381221113416","author":"R Clua Garc\u00eda","year":"2022","unstructured":"Clua Garc\u00eda R, Dumont G. From the street to the drug consumption room. Injected drug use across consumption environments. Ethnography. 2022. https:\/\/doi.org\/10.1177\/14661381221113416.","journal-title":"Ethnography"},{"issue":"2","key":"1286_CR47","doi-asserted-by":"publisher","first-page":"80","DOI":"10.4321\/S1575-06202019000200003","volume":"21","author":"E Ba\u00f1uls-Oncina","year":"2019","unstructured":"Ba\u00f1uls-Oncina E, Clua-Garc\u00eda R, Imbern\u00f3n Casas M, Jim\u00e9nez-Vinaja R. Substance use characteristics, health risk practices and associated factors among people imprisoned in Catalonia: a cross-sectional study. Rev Esp Sanid Penit. 2019;21(2):80\u20137.","journal-title":"Rev Esp Sanid Penit"},{"issue":"11","key":"1286_CR48","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1111\/jvh.12940","volume":"25","author":"A Marco","year":"2018","unstructured":"Marco A, Roget M, Cervantes M, Forn\u00e9 M, Planella R, Miquel M, Ortiz J, Navarro M, Gallego C, Vergara M, Out of Prison Study Group. Comparison of effectiveness and discontinuation of interferon-free therapy for hepatitis C in prison inmates and noninmates. J Viral Hepatitis. 2018;25(11):1280\u20136. https:\/\/doi.org\/10.1111\/jvh.12940.","journal-title":"J Viral Hepatitis"},{"issue":"1","key":"1286_CR49","doi-asserted-by":"publisher","first-page":"33","DOI":"10.18176\/resp.00047","volume":"24","author":"E Yela","year":"2022","unstructured":"Yela E, Sole N, Quintero S. Substantial concordance between transient elastography and APRI and FIB-4 combination amongst hepatitis C inmates with non advanced liver fibrosis. Revista Espa\u00f1ola de Sanidad Penitenciaria. 2022;24(1):33\u20137. https:\/\/doi.org\/10.18176\/resp.00047","journal-title":"Revista Espa\u00f1ola De Sanidad Penitenciaria"},{"key":"1286_CR50","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s11901-019-00472-2","volume":"18","author":"J Crespo","year":"2019","unstructured":"Crespo J, Llerena S, Cobo C, et al. HCV management in the incarcerated population: how do we deliver on this important front? Curr Hepatol Rep. 2019;18:259\u201367. https:\/\/doi.org\/10.1007\/s11901-019-00472-2.","journal-title":"Curr Hepatol Rep"},{"issue":"1","key":"1286_CR51","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jhep.2013.03.008","volume":"59","author":"A Marco","year":"2013","unstructured":"Marco A, Esteban JI, Sol\u00e9 C, da Silva A, Ortiz J, Roget M, Sarriera C, Teixid\u00f3 N, Guerrero RA, Cayl\u00e0 JA. Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C. J Hepatol. 2013;59(1):45\u201351. https:\/\/doi.org\/10.1016\/j.jhep.2013.03.008.","journal-title":"J Hepatol"},{"issue":"1","key":"1286_CR52","doi-asserted-by":"publisher","first-page":"28","DOI":"10.4321\/s1575-06202019000100005","volume":"21","author":"R Clua Garc\u00eda","year":"2019","unstructured":"Clua Garc\u00eda R, Ba\u00f1uls-Oncina E, Imbern\u00f3n-Casas M, Jim\u00e9nez-Vinaja R. The discourses of risk of drug users in prison. Rev Esp Sanid Penit. 2019;21(1):28\u201337. https:\/\/doi.org\/10.4321\/s1575-06202019000100005.","journal-title":"Rev Esp Sanid Penit"},{"issue":"4","key":"1286_CR53","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.eimc.2009.06.004","volume":"28","author":"S Huntington","year":"2010","unstructured":"Huntington S, Folch C, Gonz\u00e1lez V, Mero\u00f1o M, Ncube F, Casabona J. Prevalencia del VIH, hepatitis C y factores asociados n usuarios de drogas por v\u00eda parenteral seleccionados en Catalu\u00f1a. Enferm Infecc Microbiol Clin. 2010;28(4):236\u20138. https:\/\/doi.org\/10.1016\/j.eimc.2009.06.004","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"12","key":"1286_CR54","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1136\/jech-2023-220849","volume":"77","author":"CX Zhang","year":"2023","unstructured":"Zhang CX, Lewer D, Aldridge RW, Hayward AC, Cornaglia C, Trussell P, Lillford-Wildman C, Castle J, Gommon J, Campos-Matos I. Small numbers, big impact: making a utilitarian case for the contribution of inclusion health to population health in England. J Epidemiol Community Health. 2023;77(12):816\u201320. https:\/\/doi.org\/10.1136\/jech-2023-220849.","journal-title":"J Epidemiol Community Health"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01286-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-025-01286-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01286-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T08:24:38Z","timestamp":1757319878000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-025-01286-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1286"],"URL":"https:\/\/doi.org\/10.1186\/s12954-025-01286-w","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"assertion":[{"value":"13 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. The authors declare that the work reported herein did not require ethics approval because it did not involve animal or human participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"133"}}